EP2866900A2 - Beruhigende topische zusammensetzung mit paeonia- und nymphaea-extrakten - Google Patents

Beruhigende topische zusammensetzung mit paeonia- und nymphaea-extrakten

Info

Publication number
EP2866900A2
EP2866900A2 EP13731825.9A EP13731825A EP2866900A2 EP 2866900 A2 EP2866900 A2 EP 2866900A2 EP 13731825 A EP13731825 A EP 13731825A EP 2866900 A2 EP2866900 A2 EP 2866900A2
Authority
EP
European Patent Office
Prior art keywords
extract
composition
topical
composition according
nymphaea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13731825.9A
Other languages
English (en)
French (fr)
Inventor
Nadine Leconte
Philippe Bernard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe de Recherche Cosmetique SARL
Original Assignee
Societe de Recherche Cosmetique SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe de Recherche Cosmetique SARL filed Critical Societe de Recherche Cosmetique SARL
Publication of EP2866900A2 publication Critical patent/EP2866900A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/62—Nymphaeaceae (Water-lily family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Definitions

  • the present invention relates to a novel cosmetic and / or dermatological composition intended to ensure the protection of the epidermis, and more particularly to a composition based on a combination of plant extracts of the genus Paeonia and Nymphaea having a soothing biological action on the skin. skin.
  • the skin has several integrated layers, ranging from the superficial layer, the epidermis, to the deeper layers, the dermis and the hypodermis, and each has specific properties allowing the whole to react and adapt to conditions of its environment.
  • the epidermis composed mainly of keratinocytes, melanocytes and Langerhans cells, constitutes the outer layer of the skin, and plays a fundamental role in ensuring the protection and maintenance of good trophicity. That's why many compositions have been developed to protect it and improve its functions.
  • the dermis consists mainly of collagen, elastin and proteoglycans, molecules synthesized by dermal fibroblasts.
  • Collagen fibers provide the mechanical strength and texture of the skin
  • elastin is responsible for elasticity
  • proteoglycans play a major role in the structure and hydration of the skin.
  • Other cells such as macrophages and leucocytes are also present in the dermis layer.
  • the hypodermis which is the deepest layer of skin, contains lipid-producing fat cells so that the subcutaneous tissue makes a fat layer that protects muscles, bones, and internal organs from shock.
  • Enkephalins are neurotransmitters released by neurons during intense pain sensations. Their role is to inhibit the spread of pain from the nociceptors, that is to say the nerve endings in the dermis and epidermis, to the brain, responsible for the perception of pain. These are endogenous molecules that can bind to nociceptive neuron receptors and make the sensation of pain less intense, thus exerting an analgesic effect. Enkephalins can also bind to opioid receptors in the brain, which stimulates the release of dopamine by dopamine neurons and increases the sensation of pleasure.
  • the peony, genus Paeonia is a perennial, herbaceous or shrubby plant according to the various known species, belonging to the family of Paeoniaceae, originating from several regions of Europe and the Far East, in particular from China. It is well known as an ornamental plant but it has been used since ancient times as a medicinal plant in Greeks as well as in traditional Chinese medicine, especially to facilitate blood circulation or for the treatment of fevers, fibroids or abscesses.
  • US Patent Application 2005/106276 discloses an oral pharmaceutical composition useful in the treatment of diabetes and hyperlipidemia, comprising several plant extracts, including extracts of peony roots.
  • Topical compositions for the skin comprising an extract of Paeonia suffruticosa Andrews are described in patents JP 2004269382 and JP 2006124356.
  • a hydro-glycolic extract of Paeonia suffruticosa Andrews has an antioxidant activity and can be used in cosmetic anti-wrinkle compositions.
  • Patent Application JP 2002121126 describes a lotion with lightening and soothing properties of skin irritations containing a root extract of Paeonia suffruticosa.
  • Patent FR 2835430 discloses nanocapsules coated with lecithin limiting discomfort sensations caused by acrylamide polymers used as thickeners in cosmetic compositions; various actives can be incorporated into the nanocapsules, including an extract of Paeonia.
  • the blue lotus (Nymphaea caerulea), which grows on the edges of lakes and rivers, was already used in ancient Egypt for its sweet scent and its sedative medicinal qualities. Its stems, rhizomes and seeds were consumed as a food product.
  • the sacred lotus which belongs to another species, Nelumbo nucifera, different in origin and composition, contains enzymes such as methyl transferase with an anti-aging effect, as indicated in US Patent 6,468,564.
  • Nymphaea especially the lotus, and water lilies contain, in all parts, water lily and nupharine, which are alkaloids, as well as other ill-defined components.
  • the application WO 2006/000708 describes a composition associating a blue lotus extract and a poppy extract or a marshmallow extract, intended to combat the signs of skin aging, in particular expression lines.
  • the patent application KR 20090055958 describes the combination of an extract of Poncirus trifoliate and a blue lotus extract in a cosmetic composition providing an astringent effect and a protective effect against irritation of the skin.
  • the patent KR 100787782 describes the same protective effect of Nymphaea caerulea.
  • compositions of the invention are distinguished in that they comprise an extract of a plant of the species Paeonia suffruticosa in association with an extract of Nymphaea caerulea in an amount effective to provide a soothing topical action of the epidermis, as well as acceptable carriers and excipients in dermatology and cosmetology.
  • the subject of the present invention is therefore a novel cosmetic and / or dermatological composition based on extract of Paeonia suffruticosa in association with an extract of Nymphaea caerulea.
  • Such a composition has excellent properties used in cosmetics and dermatology for the protection of the skin, more particularly to provide a soothing topical action.
  • the present invention also relates to a non-therapeutic cosmetic method for providing a soothing topical action and promoting the well-being of the skin, comprising applying to the areas of the skin concerned a topical composition containing an effective amount of the combination of Paeonia suffruticosa extract and Nymphaea caerulea extract according to the present invention.
  • the subject of the invention is also a dermatological pharmaceutical composition based on an extract of Paeonia suffruticosa and an extract of Nymphaea caerulea for the protection of the epidermis and more particularly to provide a soothing topical action.
  • the invention further relates to the use of an extract of Paeonia suffruticosa and an extract of Nymphaea caerulea in combination, for the preparation of a non-therapeutic cosmetic topical composition to provide a soothing action of the epidermis.
  • compositions according to the present invention are distinguished in that they comprise an extract of Paeonia suffruticosa in combination with an extract of Nymphaea caerulea in an amount effective to provide protection of the epidermis, more particularly a soothing action, as well as carriers and excipients acceptable in dermatology and cosmetology.
  • topical compositions of the invention based on extract of Paeonia suffruticosa and extract of Nymphaea caerulea can be advantageously used in dermatology and cosmetology for the treatment and prevention of itching sensations and topical pain.
  • the active agent is constituted by the combination of extracts of the plants Nymphaea caerulea Savigny and Paeonia suffruticosa Andrews.
  • the solvent used can advantageously be selected from water, alcohols, ketones, esters, ethers, chlorinated solvents, polyols or mixtures of two or more aforementioned miscible solvents.
  • a particular extract can be made for each plant or plant organ, depending on its properties, in order to optimize the extraction yield of the desired molecules or families of molecules.
  • extract should be understood as "plant cell extract” belonging to the aforementioned group and more specifically as “cell extract of at least one plant” of the aforementioned group.
  • Said plant can be obtained by in vitro culture or in vivo.
  • in vitro culture is meant all of the techniques known to those skilled in the art that artificially allow the production of a plant or part of a plant.
  • In vivo culture means all the cultivation techniques that make it possible to obtain a plant or a part of a plant.
  • the extract may be an organ extract (root, stem, leaf, bark) or even organ cells, at least one plant of the genus Paeonia or Nymphaea, or an undifferentiated cell extract. at least one such plant.
  • Example 1 relates to the liquid extraction, but other physicochemical methods can be employed, and for example extraction with supercritical CO 2 , alone or in mixture with a co-solvent. or the extraction technique based on wave radiation, such as microwaves or ultrasound.
  • any method of extraction or purification known to those skilled in the art can be used in the invention.
  • a first step the fresh, frozen or dry plant material is crushed in a cold aqueous solution, and in a second step, the aqueous solution is filtered which is finally sterilized.
  • This aqueous solution corresponds to the extract, which can then be dried (for example by evaporation, atomization or lyophilization).
  • the extract thus obtained can be evaporated to dryness, the residue being used as it is or after purification.
  • Each extract can then be fractionated so as to enrich it with the desired active ingredient.
  • the extracts used in the present invention can be made from all accessible parts of the plants.
  • seed extracts are preferably used.
  • the extracts of Paeonia suffruticosa and Nymphaea caerulea included in the compositions according to the present invention have shown, in the in vitro tests, described in greater detail below, a marked inhibitory power of the enzymes APN (aminopeptidase N) and NEP (neutral endopeptidase). .
  • APN aminopeptidase N
  • NEP neutral endopeptidase
  • the extracts used in the compositions of the invention are generally of the order of 0.05 to 15.0%, preferably between 0.2 and 5%, for the extract of Nymphaea caerulea and of the order of 0. 0.5 to 5%, preferably from 0.1 to 3%, for the Paeonia suffruticosa extract, relative to the total weight of the composition.
  • the extracts may be mixed to be incorporated in the composition and the amount of mixture used is generally between 0.05 and 20% by weight relative to the total weight of the composition.
  • the ratio by weight of the extract of Paeonia suffruticosa to the Nymphaea caerulea extract is advantageously between 1: 1 and 1: 3, and preferably equal to 1: 2 or 1: 2.5.
  • the concentration of each of the components in the composition may be selected depending on the intended use and the mode of administration. For prolonged protective treatment, lower doses, in the form of cream or gel dosed at approximately 1 to 5% (total of the two components), are preferably used. while a spot treatment may require higher doses, for example a serum dosed between 6 and 12%, where, preferably, the doses of extracts of Nymphaea caerulea and Paeonia suffruticosa are higher.
  • these topical compositions can be used advantageously in dermatology and cosmetology for the treatment or prevention of itching sensations and topical pain.
  • These compositions can be used daily, one to several times a day, without limitation of treatment time.
  • compositions of the present invention are very well tolerated, they exhibit no phototoxicity and their application to the skin for prolonged periods of time does not imply any systemic effect.
  • compositions according to the invention may contain, in addition to an extract of Paeonia suffruticosa and an extract of Nymphaea caerulea, secondary active agents which advantageously complement their activity, and which are compatible, that is to say not liable to react on each other or to mask or limit their respective effects.
  • the complementary active ingredients are chosen for their action, for example for sun protection, anti-wrinkle effect, antiradical and antioxidant activity, anti-irritant activity, cellular nutrition, cellular respiration, hydration and cellular regeneration, anti-seborrhoeic treatments, as well as other active ingredients having an effect on the cutaneous tonicity.
  • the secondary active agents may be chosen, for example, from a mimosa seed extract and a marigold seed extract favorably acting on the stimulation of neoformed collagens, Centella asiatica, a poppy extract, a marshmallow extract, cocoa polyphenols (preferably cocoa cells), hibiscus extract (Hibiscus abelmoschus), dill extract (Peucedaneum graveolens), monomethylsilanol, proline, or shea butter.
  • a mimosa seed extract and a marigold seed extract favorably acting on the stimulation of neoformed collagens, Centella asiatica, a poppy extract, a marshmallow extract, cocoa polyphenols (preferably cocoa cells), hibiscus extract (Hibiscus abelmoschus), dill extract (Peucedaneum graveolens), monomethylsilanol, proline, or shea butter.
  • compositions in accordance with the present invention may be presented in the galenical forms conventionally used for topical application. That is to say in the form of lotion, gel, emulsion (in particular cream or milk), biphasic emulsion oil-in-water or water-in-oil, triphasic emulsion, body oil, shampoo, hair lotion, mask, ointment, ointment, protective sticks for lips, nanocapsules, liposomes or transdermal patches, containing compatible and pharmaceutically acceptable excipients and carriers. They are preferably used in the form of cream, serum and gel.
  • Topical administration are prepared by the usual techniques, and for example, in the case of a cream, by dispersion of a fatty phase in an aqueous phase to obtain an oil-in-water emulsion, or conversely to prepare a water-in-oil emulsion.
  • creams it is preferred to use lamellar structure emulsions containing little or no ethoxylated products.
  • the cosmetic compositions according to the invention may also take the form of a lotion or solution in which the extracts are in encapsulated form.
  • the microspheres according to the invention may for example consist of fatty substance, agar and water.
  • the extracts can be incorporated into liposomes, glycosphers, chylomicrons, macro-, micro-, nano-particles as well as macro-, micro- and nanocapsules vectors and also be adsorbed onto powdery organic polymers, talcs , bentonites and other mineral supports.
  • emulsions have good stability and can be stored for the time necessary for use at temperatures between 0 and 50 ° C without sedimentation of the constituents or phase separation.
  • aqueous extract preferably with a hydroalcoholic extract.
  • the topical compositions according to the invention may comprise excipients suitable for external topical administration, in particular dermatologically and cosmetologically acceptable excipients.
  • excipients suitable for external topical administration include in particular thickeners such as natural gums and synthetic polymers; gelling agents such as cellulose esters and carbopol; emollients and surfactants such as cetearyl octanoate, isopropyl myristate, cetearyl isononanoate, dimethicone, cyclomethicone, polyglyceryl 3-diisostearate, cetyl alcohol, cetyl palmitate; preservatives such as phenoxyethanol, methyl parahydroxybenzoate (methylparaben), ethyl parahydroxybenzoate (ethylparaben) and Phenonip® associating phenoxyethanol and parahydroxybenzoates; dyes; antibacterial agents, perfumes; etc.
  • compositions of the invention are moisturizing agents such as propylene glycol, glycerine, butylene glycol, the sodium salt of pyrrolidone carboxylic acid (PCA sodium), and also antioxidant vitamins such as as vitamin E, for example tocopherol acetate or tocotrienol, vitamin C, natural polyphenols. It is also possible to add ultraviolet protection agents to the composition, and for example hydrophilic or lipophilic UV-A and UV-B sunscreens chosen from benzophenone or a benzophenone derivative such as 2-hydroxy-4.
  • moisturizing agents such as propylene glycol, glycerine, butylene glycol, the sodium salt of pyrrolidone carboxylic acid (PCA sodium), and also antioxidant vitamins such as as vitamin E, for example tocopherol acetate or tocotrienol, vitamin C, natural polyphenols.
  • antioxidant vitamins such as as vitamin E, for example tocopherol acetate or tocotrienol, vitamin C, natural polyphenols.
  • UV protection agents for
  • methoxy-benzophenone (Eusolex® 4360), or a cinnamic acid ester such as octyl methoxycinnamate (Eusolex® 2292), ethyl-2-hexyl methoxyninnamate (Parsol MCX®), or a cyano-, -diphenylacrylate such as octocrylene (Eusolex® OCR), 4-methylbenzylidene camphor (Eusolex 6300®), and dibenzoylmethane derivatives such as 4-isopropyl dibenzoylmethane (Eusolex 8020), and t- Butyl-methoxy dibenzoylmethane (Parsol 1789®). It is also possible to use anti-ultraviolet screen pigments, such as, for example, titanium dioxide, zinc oxide, zirconium oxide or aluminum oxide.
  • anti-ultraviolet screen pigments such as, for example, titanium dioxide, zinc oxide,
  • the cosmetic or dermopharmaceutical use of extracts includes all body and skin care products including sun, protective and tanning products, anti-aging, anti-seborrhoeic, tonic products ensuring the improvement of the appearance of the skin, including anti-acne treatment and redness of the skin.
  • This example presents some experimental results of extraction on various selected plants.
  • a - Paeonia suffruticosa extract A - Paeonia suffruticosa extract:
  • the average yield is of the order of 15% B - Nymphaea caerulea extract:
  • the aim of this study is to determine the inhibitory powers of plant extracts against metalloproteinases aminopeptidases N (APN) and neprilysin (NEP).
  • APN metalloproteinases aminopeptidases N
  • NEP neprilysin
  • human soluble recombinant enzymes were used and their enzymatic activities evaluated using model Ala-B-naphthylamide substrates for APN and Suc-AAF-AMC for CIP.
  • NEP and APN are proteases, their enzymatic activity can be measured using appropriate substrates.
  • the most sensitive and most commonly used NEP assay is based on the Suc-Ala-Ala-Phe-AMC fluorogenic substrate (Spillantini et al., 1986, Yandle et al., 1992). NEP cleaves this substrate between Ala and Phe, and it is the addition of an excess of aminopeptidase N which releases the Phe residue and produces the AMC in fluorescent form. The fluorescence thus measured is proportional to the amount of enzyme present.
  • the APN activity is measured using the chromogenic or fluorigenic substrates L-Leucine / Alanine-para-nitroanilide or L-Leucine / Alanine-B-naphthylamide. In both cases, the APN cleaves between the amino acid Leucine or Alanine releasing either the chromophore para-nitroanilide or the fluorophore B-naphthylamide (Chen et al., 1999).
  • test conditions are as follows:
  • test conditions are as follows:
  • the active ingredient resulting from a 50/50 Paeonia / Nymphaea mixture thus produced has an inhibitory activity of the NEP and APN enzymes isolated with an IC50 of 36 mg / ml and 129 mg / ml, respectively.
  • a cosmetic cream is prepared having the composition indicated below.
  • Vegetable oils rosehip oil muscat / macadamia oil 4,5
  • This cream is used once or twice a day by application to the areas of the skin to be treated.
  • a serum is prepared having the weight composition indicated below.
  • This serum can be used once or twice a day on the areas of the skin to be treated, possibly in addition to treatment with a cream.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
EP13731825.9A 2012-06-27 2013-06-27 Beruhigende topische zusammensetzung mit paeonia- und nymphaea-extrakten Withdrawn EP2866900A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1256091A FR2992561B1 (fr) 2012-06-27 2012-06-27 Composition topique apaisante a base d'extraits de paeonia et de nymphaea
PCT/EP2013/063543 WO2014001465A2 (fr) 2012-06-27 2013-06-27 Composition topique apaisante a base d'extraits de paeonia et de nymphaea

Publications (1)

Publication Number Publication Date
EP2866900A2 true EP2866900A2 (de) 2015-05-06

Family

ID=48699835

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13731825.9A Withdrawn EP2866900A2 (de) 2012-06-27 2013-06-27 Beruhigende topische zusammensetzung mit paeonia- und nymphaea-extrakten

Country Status (3)

Country Link
EP (1) EP2866900A2 (de)
FR (1) FR2992561B1 (de)
WO (1) WO2014001465A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3062794B1 (fr) * 2017-02-14 2021-11-26 Sokhna Racky Ba Procede de traitement cosmetique ternaire destine au sevrage progressif des peaux ayant subit une depigmentation volontaire tout en prevenant et corrigeant les signes du vieillissement.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468564B1 (en) 1997-02-21 2002-10-22 Clientele Beauty, Inc. Topical compositions containing lotus for skin treatment
JP2002121126A (ja) * 2000-10-13 2002-04-23 Noevir Co Ltd 皮膚外用剤
AU2002221512A1 (en) 2001-11-29 2003-06-10 Jiangsu Kanion Pharmaceutical Co., Ltd A pharmaceutical composition made from chinese traditional medecine and method of producing thereof
FR2835430A1 (fr) * 2002-05-31 2003-08-08 Oreal Composition comprenant des nanocapsules enrobees de lecithine et un polymere d'acrylamide
JP2004269382A (ja) 2003-03-06 2004-09-30 Shiseido Co Ltd セリンプロテアーゼ阻害剤
WO2006000708A1 (fr) 2004-06-09 2006-01-05 Laboratoire Nuxe Composition comprenant un extrait de lotus bleu a effet decontractant de la peau.
JP2006124356A (ja) 2004-11-01 2006-05-18 Ichimaru Pharcos Co Ltd インターロイキン−１α産生阻害剤
CN1977817A (zh) * 2005-12-02 2007-06-13 上海莲氏轩生物工程有限公司 植物护理功能液
KR100787782B1 (ko) * 2006-10-16 2007-12-21 주식회사 코리아나화장품 블루 로터스 추출물을 유효성분으로 함유하는 피부 자극완화용 화장료 조성물
KR20080098925A (ko) 2007-05-08 2008-11-12 (주)더페이스샵코리아 목단피 추출물을 함유하는 화장료 조성물
KR100946584B1 (ko) * 2007-11-29 2010-03-09 주식회사 코리아나화장품 지실 추출물 및 블루로터스 추출물을 함유하는 수렴 및 피부 자극 완화용 화장료 조성물
CN101953483A (zh) * 2009-07-20 2011-01-26 胡成爱 一种鲜花果粒南瓜汁

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2014001465A2 *

Also Published As

Publication number Publication date
FR2992561B1 (fr) 2015-09-18
WO2014001465A3 (fr) 2014-02-27
FR2992561A1 (fr) 2014-01-03
WO2014001465A2 (fr) 2014-01-03

Similar Documents

Publication Publication Date Title
FR2814950A1 (fr) Utilisation d'au moins un extrait d'au moins un vegetal de la famille des ericaceae, dans des compositions destinees a traiter les signes cutanes du vieillissement
EP2691074A1 (de) Zusammensetzung auf der basis von camellia japonica und polygonum hydropiper zum schutz der haut
EP0946138A2 (de) Verwendung eines potentilla erecta extraktes im kosmetischen und pharmazeutischen gebiet
EP1768684A1 (de) Zusammensetzung mit extrakt von blauem lotus mit entspannender wirkung auf die haut
FR3051369B1 (fr) Extraits de faine de hetre, compositions et utilisations
EP2291173B1 (de) Kombination von passionsblumen- und alkaner-extrakten zur verwendung in kosmetika
EP2699227B1 (de) Pflanzenextraktkomplex zum schutz der haut
WO2014001465A2 (fr) Composition topique apaisante a base d'extraits de paeonia et de nymphaea
EP3237072B1 (de) Verwendung eines extraktes von lythrum salicaria
EP2811978B1 (de) Verwendung eines extraktes aus der apfelbaumrinde zur kosmetischen verhinderung von alterserscheinungnen der haut
EP2811977B1 (de) Verwendung eines apfelbaumblattextraktes in einer kosmetischen haut-straffungs zusammensetzung
EP2777709B1 (de) Verwendung eines lipophilen Wasserhyazinthen-Extrakts zur Versorgung der Haut mit Feuchtigkeit
FR2859102A1 (fr) Utilisation d'un extrait de rhodiola crenulata par voie topique
FR2885300A1 (fr) Composition topique pour la protection de l'epiderme
EP1879539B1 (de) Hautschutzzusammensetzung auf der basis von araukariensamenextrakten
FR2885052A1 (fr) Utilisation d'un extrait de maca pour proteger la microcirculation cutanee
FR2871382A1 (fr) Composition comprenant un complexe d'extraits vegetaux, a effet decontractant de la peau
FR3099702A1 (fr) Nouvelle utilisation cosmétique d’un extrait d’Epilobium angustifolium
FR3110421A1 (fr) Extrait de Narcissus poeticus pour son utilisation cosmétique
FR3099701A1 (fr) Nouvelle utilisation cosmétique d’une combinaison d’oenothéine-B et de quercétine-3-O-glucuronide
FR2885049A1 (fr) Composition a base d'extraits de graines d'araucaria pour la protection de l'epiderme.
FR2871380A1 (fr) Composition comprenant un extrait vegetal a effet decontractant de la peau
WO2012172200A1 (fr) Composition a base de samanea saman pour la protection de la peau
FR2973695A1 (fr) Composition a base de cafeine et de triacanthine pour le traitement des surcharges adipeuses.
WO2012140352A2 (fr) Composition à base de gleditsia pour le traitement des surcharges adipeuses.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150106

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SOCIETE DE RECHERCHE COSMETIQUE SARL

17Q First examination report despatched

Effective date: 20170119

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170530